ArticleRadiation oncology (London, England)2026
A novel strategy for soft tissue sarcoma lattice radiotherapy: integrating X-ray andγ-ray technologies to optimize dose delivery.
Article in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe TaiChi radiotherapy platform is an innovative system integrating linear accelerator (LINAC) and Gamma Knife technologies, approved by both NMPA and FDA. This hybrid design enables bimodal (X-ray and γ-ray) radiation delivery, offering enhanced flexibility for treatment planning and dose delivery. This study quantitatively evaluates its dosimetric performance for lattice radiotherapy (LRT) in soft tissue sarcoma (STS), specifically comparing its dose escalation potential and normal tissue sparing to conventional C-arm LINAC.
methodsA dosimetric analysis was conducted on 10 STS cases. The treatment combined LRT (15 Gy single fraction to spherical vertices within the Gross tumor volume (GTV)) with conventionally fractionated external beam radiotherapy (50 Gy/25F to the planning target volume (PTV)). TaiChi utilized its dual-modality capability, employing γ-ray focusing for vertex dose escalation and optimizing the LINAC for conventional coverage. Plans were compared on high-dose vertex coverage, dose fall-off, and organ-at-risk (OAR) sparing.
resultsTaiChi demonstrated superior dosimetric performance across all evaluated parameters. For vertex coverage, TaiChi achieved significantly higher D
conclusionThe TaiChi platform's innovative integration of LINAC and Gamma Knife technologies provides distinct dosimetric advantages for STS LRT, enabling superior dose escalation to high-dose vertex regions while maintaining steep dose gradients and effective normal tissue sparing. These capabilities position TaiChi as a promising platform for advancing LRT applications. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.